FMBTD
PLX icon

First Midwest Bank Trust Division’s Protalix BioTherapeutics PLX Stock Holding History

First Midwest Bank Trust Division’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-3,723
Closed -$169K – 398
2013
Q3 		$169K Hold
3,723
– – 0.03% 345
2013
Q2 		$183K Buy
+3,723
New +$198K 0.04% 326

Other funds holding PLX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

First Midwest Bank Trust Division's PLX Position: Q4 2013 in Review

First Midwest Bank Trust Division sold out of Protalix BioTherapeutics (PLX) in Q4 2013, closing a stake of 3,723 shares — an estimated $169K sold.

First Midwest Bank Trust Division first reported a position in PLX in Q2 2013 and held it in 2 quarters. The position peaked at $183K in Q2 2013. 45 funds tracked by Wall St. Rank hold PLX as of Q4 2013.

  • First Midwest Bank Trust Division reported no remaining Protalix BioTherapeutics position as of Q4 2013 after selling out during the quarter.
  • First Midwest Bank Trust Division sold 3,723 Protalix BioTherapeutics shares in Q4 2013, an estimated $169K.
  • First Midwest Bank Trust Division first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 2 quarters.
  • First Midwest Bank Trust Division's Protalix BioTherapeutics position peaked at $183K in Q2 2013.
  • 45 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2013.

Based on First Midwest Bank Trust Division's 13F filing for Q4 2013, filed 13 Jan 2014.